BDRX
Biodexa Pharmaceuticals PlcNASDAQHealthcare$4.37-11.37%ClosedMarket Cap: $3.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.06
P/S
0.00
EV/EBITDA
0.92
DCF Value
$208.13
FCF Yield
-1148.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.8%
ROA
-35.1%
ROIC
-72.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-4.7M | $-2.6M | $0.00 | — |
| FY 2025 | $0.00 | -Infinity% | $-8.3M | $-6.2M | $-10.00 | — |
| Q2 2025 | $0.00 | -Infinity% | $-4.0M | $-3.8M | $-1,506,000.00 | — |
| Q4 2024 | $0.00 | -Infinity% | $-5.0M | $-2.4M | $-365,000.00 | — |
| FY 2024 | $0.00 | -Infinity% | $-9.2M | $-5.7M | $-1,157,000.00 | — |
| Q2 2024 | $0.00 | -Infinity% | $-4.2M | $-3.3M | $-792,000.00 | — |
| Q4 2023 | $83.0K | -2612.0% | $-3.8M | $-3.5M | $-113,000.00 | — |
| FY 2023 | $381.0K | -967.5% | $-8.0M | $-7.1M | $-229,000.00 | — |
| Q2 2023 | $298.0K | -655.4% | $-4.2M | $-3.6M | $-219,000.00 | — |
| Q4 2022 | $231.0K | -1068.0% | $-3.8M | $-4.6M | $-2,967,000.00 | — |
| FY 2022 | $699.0K | -631.2% | $-8.9M | $-7.7M | $-4,943,000.00 | — |
| Q2 2022 | $468.0K | -415.6% | $-3.8M | $-3.1M | $-1,976,000.00 | — |